Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1413-1420

  Stefancikova, Lenka ^a,b   Moulis, Mojmir ^a   Fabian, Pavel ^c   Vasova, Ingrid ^a   Zedek, Frantisek ^b   Ravcukova, Barbora ^d   Muzik, Jan ^b   Kuglik, Petr ^a,b   Vranova, Vladimira ^a,b   Falkova, Iva ^a   Hrabalkova, Renata ^a   Smardova, Jana ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d CENTRE FOR CARDIOVASCULAR SURGERY AND TRANSPLANTATION   (Czech Republic)

Author keywords

Diffuse large B cell lymphoma; Functional status by analysis of separated alleles in yeast; Overall survival; Progression free survival; Tumor suppressor p53

Indexed keywords

ATM PROTEIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN P53; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DNA SEQUENCE; FEMALE; FUNCTIONAL STATUS; GENE DELETION; GENE MUTATION; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NONSENSE MEDIATED MRNA DECAY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION; PREDNISONE; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE; YOUNG ADULT;

EID: 80054816994     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1170     Document Type: Article

References (55)

1. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006, 1993. (Pubitemid 23095683)
2. Kramer MH, Hermans J, Wijburg E, et al.: Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92: 3152-3162, 1998. (Pubitemid 28492322)
3. Lossos IS, Okada CY, Tibshirani R, et al.: Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 95: 1797-1803, 2000. (Pubitemid 30120845)
4. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000. (Pubitemid 30082188)
5. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947, 2002.
6. Rosenwald A, Wright G, Leroy K, et al.: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198: 851-862, 2003. (Pubitemid 37152922)
7. Savage KJ, Monti S, Kutok JL, et al.: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102: 3871-3879, 2003. (Pubitemid 37486965)
8. Staudt LM and Dave S: The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 87: 163-208, 2005. (Pubitemid 41135900)
9. Hans CP, Weisenburger DD, Greiner TC, et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282, 2004. (Pubitemid 38029949)
10. Chang CC, McClintock S, Cleveland RP, et al.: Immunohisto- chemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28: 464-470, 2004. (Pubitemid 38436519)
11. Muris JJ, Meijer CJ, Vos W, et al.: Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 208: 714-723, 2006.
12. Choi WW, Weisenburger DD, Greiner TC, et al.: A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15: 5494-5502, 2009.
13. Lossos IS: Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 23: 6351-6357, 2005.
14. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al.: Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109: 4930-4935, 2007. (Pubitemid 46827791)
15. Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359-7368, 2003.
16. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002. (Pubitemid 34438862)
17. Pfreundschuh M, Trümper L, Osterborg A, et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379-391, 2006.
18. Bea S and Campo E: Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior. Haematologica 93: 641-645, 2008. (Pubitemid 351669301)
19. Ye BH, Lista F, Le Coco F, et al.: Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262: 747-750, 1993. (Pubitemid 23350695)
20. Møller MB, Ino Y, Gerdes AM, Skjødt K, Louis DN and Pedersen NT: Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 13: 453-459, 1999. (Pubitemid 29108084)
21. Winter JN, Weller EA, Horning SJ, et al.: Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 107: 4207-4213, 2006. (Pubitemid 43801342)
22. Mounier N, Briere J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101: 4279-4284, 2003. (Pubitemid 36857789)
23. Ichikawa A, Kinoshita T, Watanabe T, et al.: Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337: 529-534, 1997. (Pubitemid 27352019)
24. Møller MB, Gerdes AM, Skjødt K, Mortensen LS and Pedersen NT: Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin Cancer Res 5: 1085-1091, 1999. (Pubitemid 29233223)
25. Young KH, Weisenburger DD, Dave BJ, et al.: Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 110: 4396-4405, 2007. (Pubitemid 351377806)
26. Young KH, Leroy K, Møller MB, et al.: Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 112: 3088-3098, 2008.
27. Zainuddin N, Berglund M, Wanders A, et al.: TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res 33: 60-66, 2009.
28. Leroy K, Haioun C, Lepage E, et al.: p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13: 1108-1115, 2002.
29. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005. (Pubitemid 40638098)
30. Sherr CJ: Principles of tumor suppression. Cell 116: 235-246, 2004.
31. Lowe SW, Cepero E and Evan G: Intrinsic tumour suppression. Nature 432: 307-315, 2004. (Pubitemid 39551658)
32. Brosh R and Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713, 2009.
33. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997. (Pubitemid 27220766)
34. Honda R, Tanaka H and Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27, 1997. (Pubitemid 28037193)
35. Wu XW, Bayle JH, Olson D and Levine AJ: The p53 mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132, 1993. (Pubitemid 23207405)
36. Rotman G and Shiloh Y: ATM: from gene to function. Hum Mol Genet 7: 1555-1563, 1998. (Pubitemid 28464032)
37. Grønbaek K, Worm J, Ralfkiaer E, Ahrenkiel V, Hokland P and Guldberg P: ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood 100: 1430-1437, 2002. (Pubitemid 34864302)
38. Jiang H, Reinhardt HC, Bartkova J, et al.: The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23: 1895-1909, 2009.
39. Cuneo A, Bigoni R, Rigolin GM, et al.: Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: correlation with clinicobiologic features. J Clin Oncol 18: 2607-2614, 2000. (Pubitemid 30432528)
40. Greiner TC, Dasgupta C, Ho VV, et al.: Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 103: 2352-2357, 2006. (Pubitemid 43271673)
41. Camacho E, Hernandez L, Hernandez S, et al.: ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol- 3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99: 238-244, 2002.
42. Fang NY, Greiner TC, Weisenburger DD, et al.: Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci USA 100: 5372-5377, 2003. (Pubitemid 36542712)
43. Flaman JM, Frebourg T, Moreau V, et al.: A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963-3967, 1995.
44. Smardova J, Nemajerova A, Trbusek M, Vagunda V and Kovarik J: Rare somatic p53 mutation identified in breast cancer: a case report. Tumor Biol 22: 59-66, 2001. (Pubitemid 32010738)
45. Ishioka C, Frebourg T, Yan YX, et al.: Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5: 124-129, 1993. (Pubitemid 23293446)
46. Waridel F, Estreicher A, Bron L, et al.: Field cancerisation and polyclonal p53 mutation in the upper aerodigestive tract. Oncogene 14: 163-169, 1997. (Pubitemid 27068302)
47. Silva AL and Romao L: The mammalian nonsense-mediated mRNA decay pathway: To decay or not to decay! Which players make the decision? FEBS Lett 583: 499-505, 2009.
48. Stefancikova L, Moulis M, Fabian P, et al.: Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. Int J Oncol 36: 699-706, 2010.
49. Grochova D, Vankova J, Damborsky J, et al.: Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast. Oncogene 27: 1243-1252, 2008. (Pubitemid 351294697)
50. Koduru PR, Raju K, Vadmal V, et al.: Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 90: 4078-4091, 1997. (Pubitemid 27484063)
51. Sanchez-Beato M, Saez AI, Navas IC, et al.: Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 159: 205-213, 2001. (Pubitemid 33704205)
52. Barrans SL, Carter I, Owen RG, et al.: Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99: 1136-1143, 2002. (Pubitemid 34547064)
53. Mitani S, Kamata H, Fujiwara M, et al.: Missense mutation with/without nonsense mutation of the p53 gene is associated with large cell morphology in human malignant lymphoma. Pathol Int 57: 430-436, 2007. (Pubitemid 46976410)
54. Villuendas R, Piris MA, Algara P, et al.: The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 82: 3151-3156, 1993. (Pubitemid 23334944)
55. Osada M, Ishioka C, Ichinohasama R, et al.: Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma. Anticancer Drug Des 14: 107-114, 1999. (Pubitemid 29292307)